Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Conditions

• Advanced or Metastatic Solid Malignancies

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Sitravatinib — DRUG
  Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
• Nivolumab — DRUG
  Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
• Pembrolizumab — DRUG
  Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
• Enfortumab Vedotin-Ejfv — DRUG
  Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
• Ipilimumab — DRUG
  Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody

Study Details

A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies

Key Dates

Start date

Jun 29, 2021

Status verified

Oct 2025

Primary completion

Apr 21, 2025

Completion

Sep 25, 2025

Study Design

Enrollment

52 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Phase 2/3: Open label extension of parent study
  The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.

Primary Outcome Measure

Frequency of subjects experiencing treatment-related AEs. [ Time Frame: 24 Months ]

Locations (13)

Find similar trials in Littleton, CO